Sigma Healthcare Limited
SIG
Rangering i aksjer
#1057
Sigma Healthcare Limited, together with its various operating divisions,... Sigma Healthcare Limited, together with its various operating divisions, primarily engages in the wholesale supply and distribution of pharmaceutical goods across Australia. The company also manages a significant network of approximately 1,200 retail pharmacies, encompassing both independent outlets and prominent brands such as Amcal, Discount Drug Stores, Guardian, WholeLife, and PharmaSave. Beyond retail, its comprehensive service portfolio includes wholesale provisions for hospital pharmacies, as well as crucial dose administration aid services delivered to the aged care sector, community pharmacies, and directly to individuals in their homes. Furthermore, Sigma offers advanced technology solutions and data analytics, alongside product development and support for its range of private and exclusive label products. It is also a key supplier of medical consumables and devices to a broad spectrum of customers, from pharmacies and aged care facilities to hospitals and clinics. In addition, the company provides contract logistics services to pharmaceutical manufacturers and other supply partners. Established in 1912, Sigma Healthcare Limited maintains its corporate headquarters in Rowville, Australia.
Aksjekurs
$1.94
Markedsverdi
$22.27B
Endring (1 dag)
-0.72%
Endring (1 år)
-1.89%
Land
AU
Handel Sigma Healthcare Limited (SIG)
Kategori
Healthcare
P/E-forhold for Sigma Healthcare Limited (SIG)
P/E-forhold per October 2026 TTM: 45.62
Ifølge Sigma Healthcare Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 45.62. Ved slutten av 2024 hadde selskapet en P/E på 234.02.
P/E-forholdshistorikk for Sigma Healthcare Limited fra 2001 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 45.62 | -114.00% |
| 2025 | -325.86 | -239.25% |
| 2024 | 234.02 | -26.24% |
| 2023 | 317.28 | -665.12% |
| 2022 | -56.14 | -501.98% |
| 2021 | 13.97 | -132.08% |
| 2020 | -43.54 | -428.15% |
| 2019 | 13.27 | -11.29% |
| 2018 | 14.96 | -30.16% |
| 2017 | 21.42 | 38.38% |
| 2016 | 15.48 | 4.98% |
| 2015 | 14.74 | 39.21% |
| 2014 | 10.59 | -78.60% |
| 2013 | 49.48 | 283.29% |
| 2012 | 12.91 | -743.40% |
| 2011 | -2.01 | -2.21% |
| 2010 | -2.05 | -110.26% |
| 2009 | 19.99 | -22.66% |
| 2008 | 25.85 | -25.53% |
| 2007 | 34.72 | -2.21% |
| 2006 | 35.50 | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | 336.99 | -27.92% |
| 2002 | 467.50 | -41.33% |
| 2001 | 796.84 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 26.02 | -42.96% |
US
|
|
| - | - |
US
|
|
| 34.08 | -25.30% |
US
|
|
| - | - |
US
|
|
| 24.73 | -45.79% |
US
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.